Back to Funding Hub
Spain

Spain R&D Tax Credit 2026

Funding Amount
25-42% tax credit on R&D expenditure

Program Overview

Spain's R&D Tax Credit offers a 25% tax credit for expenses from R&D activities, with an enhanced 42% credit rate for expenses exceeding the average R&D expenditure from the previous two years. This makes Spain one of Europe's most generous jurisdictions for R&D tax incentives.

Credit Rates and Structure

Base R&D activities qualify for 25% tax credit. For R&D expenses higher than the 2-year average, the excess qualifies for 42% credit. Additionally: 17% credit for qualified researchers dedicated exclusively to R&D, 8% credit for investments in assets dedicated exclusively to R&D, and 12% credit for technological innovation activities beyond R&D.

Refundability and Payment

A unique feature: up to 80% of R&D and technological innovation tax credits may reduce tax liability to zero, with any excess (up to 80%) refundable by tax authorities. This costs 20% of credits applied but provides immediate cash benefit for startups with limited tax liabilities. R&D credits can be excluded from standard tax credit limits.

Qualifying Activities and Expenditure

Qualifying R&D includes systematic investigative or experimental activities seeking scientific or technological advancement. Eligible expenses: employee salaries for R&D staff, materials and supplies consumed, proportionate overhead costs, payments to universities or research centers for contracted R&D, and depreciation of assets used exclusively for R&D.

Claiming Process

File R&D tax credit claims with annual corporate tax return. Maintain detailed documentation: project descriptions with technical challenges, expenditure breakdowns by category, time logs for researcher activities, and technical reports demonstrating innovation. Consider engaging R&D tax specialists to maximize claims and ensure compliance with Spanish tax authority requirements.

Common Questions

Spain offers one of Europe's most generous R&D tax credit schemes with a base deduction of 25% on qualifying R&D expenditure, increasing to 42% for spending that exceeds the average of the previous two years. Technological innovation activities qualify for a separate 12% deduction. Companies can also claim additional deductions for R&D personnel costs and investments in dedicated R&D assets and equipment.

Yes, Spain allows companies to request a cash refund of unused R&D tax credits with a discount applied to the credit amount, subject to certain conditions. This monetization option is particularly valuable for pre-revenue startups and companies investing heavily in R&D before generating taxable profits. The refund mechanism ensures that the incentive benefits innovative companies regardless of their current profitability status.

Spanish legislation provides distinct rates: pure R&D commands twenty-five percent base deduction with enhancements for spending growth, while technological innovation qualifies for twelve percent. This bifurcated structure incentivizes genuinely groundbreaking research over incremental modifications. Companies must carefully categorize activities to maximize fiscal advantages under each qualifying tier.

Spain allows converting unused deductions into direct refunds under specific conditions. Companies obtain binding assessment from the Ministry of Science, maintain dedicated R&D workforce levels, and reinvest in research activities. Annual refundable amounts are capped, and credits must remain unutilized for one fiscal year before requesting treasury disbursement of accumulated balances.

Pharmaceutical enterprises conducting preclinical toxicology assessments, bioequivalence studies, and Phase I through Phase III clinical investigations within Spanish territory can classify substantial portions of trial expenditure as qualifying R&D activity. Laboratory reagent procurement, bioinformatics data processing, and regulatory dossier compilation represent eligible cost categories. Contract research organization fees paid to Spanish facilities qualify when the sponsoring entity retains intellectual property ownership. Orphan drug designation studies and companion diagnostic development activities receive particularly favorable treatment.

Transfer pricing documentation must demonstrate arm's-length compensation for intangible asset development contributions between Spanish subsidiaries and foreign parent entities. Permanent establishment risk assessments evaluate whether contracted research personnel create taxable nexus obligations in third jurisdictions. Advance pricing agreements with Spanish tax authorities provide certainty regarding intercompany royalty payment deductibility. Functional analysis benchmarking studies comparing Spanish R&D cost centers against comparable independent laboratories substantiate allocation methodologies.

References

  1. R&D+i Tax Deductions - Agencia Tributaria. Agencia Tributaria (Spanish Tax Agency) (2025). View source
  2. Spain Corporate Tax Credits and Incentives. PwC (2025). View source
  3. Spain R&D Tax Incentives - OECD INNOTAX. OECD (2024). View source

Ready to Explore AI Training in Spain?

We help organizations navigate funding programs and deliver claimable AI training. Let us know what you are working on.

Start a Conversation